Phase 1 Study of BMS-833923 (XL139)

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects with Solid Tumors

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221644

Enrollment

Registered

2011-11-08

Start date

2011-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

investigational material(s) Generic name etc : BMS-833923 (XL139) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigationa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with advanced or metastatic solid tumors refractory to, or relapsed from, standard therapies or for which there is no known effective treatment.

Exclusion criteria

Exclusion criteria: Subjects with symptomatic brain metastasis or active brain metastasis requiring treatments. Inability to swallow oral medication. Uncontrolled or significant cardiovascular disease. Inadequate bone marrow function. Inadequate hepatic function. Inadequate renal function. Pancreatitis.

Design outcomes

Primary

Measure	Time frame
Incidence of Dose Limiting Toxicity (DLT) and observed adverse events.	—

Secondary

Measure	Time frame
The number of subjects experienced DLT. PK parameters (Cmax, Cmin, Tmax, AUC(TAU), T-half,eff, AI). Best overall response.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026